Vincent R G, Mehta C R, Tucker R D, Mountain C F, Cohen M, Wilson H E, Vogel C
Cancer. 1980 Jul 15;46(2):256-60. doi: 10.1002/1097-0142(19800715)46:2<256::aid-cncr2820460206>3.0.co;2-q.
Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significant difference existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.
210例晚期肺腺癌患者进入一项双臂随机试验。比较了环磷酰胺+洛莫司汀+甲氨蝶呤与阿霉素和丙卡巴肼的疗效。环磷酰胺+洛莫司汀+甲氨蝶呤方案的肿瘤缓解率显著高于阿霉素和丙卡巴肼方案。两种治疗方案在生存率方面无显著差异。初始身体状况、治疗前体重减轻和治疗反应均被发现是重要的预后因素。两个治疗组中，缓解者的中位生存时间为31.7周，未缓解者为15.8周。
